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Background: To investigate access to treatment for chronic hepatitis B/C among six vulnerable patient/population
groups at-risk of infection: undocumented migrants, asylum seekers, people without health insurance, people
with state insurance, people who inject drugs (PWID) and people abusing alcohol. Methods: An online survey
among experts in gastroenterology, hepatology and infectious diseases in 2012 in six EU countries: Germany,
Hungary, Italy, the Netherlands, Spain and the UK. A four-point ordinal scale measured access to treatment
(no, some, significant or complete restriction). Results: From 235 recipients, 64 responses were received (27%).
Differences in access between and within countries were reported for all groups except people with state
insurance. Most professionals, other than in Spain and Hungary, reported no or few restrictions for PWID.
Significant/complete treatment restriction was reported for all groups by the majority in Hungary and Spain,
while Italian respondents reported no/few restrictions. Significant/complete restriction was reported for undocu-
mented migrants and people without health insurance in the UK and Spain. Opinion about undocumented
migrants in Germany and the Netherlands was divergent. Conclusions: Although effective chronic hepatitis B/C
treatment exists, limited access among vulnerable patient populations was seen in all study countries. Discordance
of opinion about restrictions within countries is seen, especially for groups for whom the health care system
determines treatment access, such as undocumented migrants, asylum seekers and people without health
insurance. This suggests low awareness, or lack, of entitlement guidance among clinicians. Expanding
treatment access among risk groups will contribute to reducing chronic viral hepatitis-associated avoidable
morbidity and mortality.
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Introduction
Infection with hepatitis B (HBV) virus and C virus (HCV) affectsthe liver and can result in a broad spectrum of disease outcomes.
People with chronic hepatitis B (CHB) and/or C virus infection
remain infectious and are at risk of serious liver disease such as
cirrhosis or hepatocellular cancer (HCC). Worldwide, chronic viral
hepatitis infection is responsible for over 70% of deaths due to HCC
and nearly 60% of deaths due to cirrhosis.1,2 Around 480–520
million people are estimated to be chronically infected with HBV/
HCV, although there are strong regional differences in burden of
disease. The largest burden of HCV is found in Central/Eastern Asia
and the Middle East whereas HBV prevalence is highest in Sub-
Saharan Africa and Asia.3 There is also some geographical
variation in HBV and HCV prevalence in Europe.4 Most CHB
infections in Europe are detected among migrants from HBV-
endemic areas. Chronic hepatitis C is also more common among
migrants (due to non-sterile health care, dental and shaving
practices and equipment in low-and middle-income countries of
origin), although a large proportion is found among current/past
injecting drug users.5 Differences in the proportion of chronic
hepatitis C cases detected among migrants compared with people
who inject drugs (PWID) are reported in Europe; in the United
Kingdom (UK), e.g. PWID account for over 90% of cases,6
whereas migrants from endemic areas account for most infections
in the Netherlands, Germany, Italy and Spain.7,8
Chronic infections are mostly asymptomatic and progress over a
period of 20–30 years towards cirrhosis and HCC. Effective
treatment exists for both chronic hepatitis B and C and, from
2014, highly effective direct-acting antivirals that can cure chronic
hepatitis C are available.9,10 Early identification, before decompen-
sation and/or development of HCC, is strongly associated with
improved treatment outcome.11 Therefore, screening for chronic
infection among a range of risk groups, but particularly among
people born in hepatitis B/C endemic areas and PWID, is
recommend as a form of secondary prevention.6,12 Screening
among migrants from areas with >2% viral hepatitis prevalence
has also been shown to be cost-effective.13 Although incident cases
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are decreasing, models predict that the peak mortality for HCV-
related causes is ahead of us and a large undiagnosed burden of
disease exists; that the proportion of people infected that are
unaware, undiagnosed and not in treatment is considerably larger
than the proportion diagnosed and in treatment.8 For example, a
large screening study in primary care in Germany found that
85% of HBsAg and 65% of anti-HCV positive individuals were
unaware of their infection.14 However, there are few published
studies of migrant-specific viral hepatitis screening programmes in
Europe.15–18 PWID-specific studies are more common although
screening among this high-risk group is not systematic in any
European country, due to both health system and patient-group
characteristics, including criminalisation.19 The literature also
suggests that migrant populations experience difficulties in
accessing health care and experience worse health outcomes as a
result.20–22 Little is known about access to treatment across
Europe among marginalised groups at risk of hepatitis B/C infection.
We aimed to investigate access to treatment for chronic hepatitis
B/C in six EU countries (Germany, Hungary, Italy, the Netherlands,
Spain and the United Kingdom (UK)) among six patient/population
groups. These included undocumented migrants, asylum seekers,
people without health insurance, people with state insurance,
PWID and people who abuse alcohol. This study is part of
HEPscreen,23 an EU Health Programme-funded project focused on
screening for chronic viral hepatitis among migrants in Europe.
Methods
A semi-quantitative online survey was developed, pilot tested and
translated into the national languages of the study countries and
uploaded into Lime SurveyTM open source online survey software.
The aim of the survey was to understand care pathways in clinical
services for patients diagnosed with chronic viral hepatitis in the six
study countries using nominal, ordinal and qualitative questions.
We report here the results focused on access to treatment among
specific patient/population groups; the more clinically focused
questions about the use of diagnostics, referral and the role of
different clinical specialists are to be reported elsewhere. The
survey was sent to experts in hepatology, gastroenterology and
infectious diseases based in six EU countries: Germany, Hungary,
Italy, the Netherlands, Spain and the UK. We identified experts via
board membership of clinical and professional associations,
leadership of hepatology treatment and research centres, and
authors of relevant scientific articles. Our objective was to reach a
sample of 5–10 knowledgeable experts from each country rather
than develop a representative sampling frame. In recognition of
the low response rate to surveys among practising clinicians, we
identified a large sample of 243 recipients.
We asked whether treatment for chronic hepatitis was restricted
for each of the six patient/population groups and developed a four-
point ordinal scale to measure this: ‘no restrictions’, ‘some restric-
tions’, ‘significant restrictions’ and ‘completely restricted’. An
‘unsure’ option was also available. We collected respondent data
by asking for organisation type and whether they were involved in
the care of patients/had a clinical role. Among those with a clinical
role, we asked for their medical specialism and used a three-point
ordinal scale to gather data on frequency of seeing chronic hepatitis
B/C patients (weekly, monthly and annually). Recipients were
contacted via e-mail in July 2012 and further reminded twice
during data collection. The survey closed in September 2012. Data
was exported from Lime Survey to SPSS 19.0.2 for descriptive
analysis of frequencies and proportions.
Results
Respondents
Eight of 243 recipients actively opted out after receiving the
invitation. From the remaining 235 recipients, a total of 64
responses were received (27%). The response rate differed across
the six study countries: 11% in Germany, 24% in the UK, 25% in
Spain, 27% in Hungary, 48% in the Netherlands and 60% in Italy. In
five of the six countries, Spain being the exception, we achieved the
target of between 5 and 10 experts. Three of these 64 respondents
had not completed the whole survey and were excluded. All but
three of the 61 are currently involved in the care of patients and
95% of these see chronic hepatitis patients on a weekly basis. Due to
the clinical nature of the topics, analysis was restricted to only data
supplied by those with a clinical role (n= 58). Of these, the majority
(77%) are specialists in gastroenterology or hepatology, a fifth are
specialists in infectious disease, and a small number (n= 3) are
community/practice nurses. The respondent profile pattern in all
countries was similar to this overall pattern except in Italy and the
Netherlands; in Italy, nearly half (44%) are specialists in infectious
disease and in the Netherlands, a larger proportion (81%) are
gastroenterologists/hepatologists. Most are based in academic
(61%) or general hospitals (28%).
Access to treatment for undocumented migrants
Most respondents in all countries but Italy reported that antiviral
treatment for chronic viral hepatitis is completely or significantly
restricted for undocumented migrants. This is especially so in
Hungary where three quarters reported treatment to be completely
restricted, in the UK where two thirds indicated significant or
complete restriction, and in Spain where three quarters selected sig-
nificant or complete restriction. Over three quarters in Italy reported
that there are no or some restrictions in place. Opinion was divided
in the Netherlands and Germany (table 1).
Access to treatment for asylum seekers
Two-thirds of those in Hungary and half in Spain reported signifi-
cant or complete restrictions in treatment for chronic hepatitis
patients with asylum seeker status. In contrast, all but one
respondent in Germany, over half in the UK, and three quarters of
those in the Netherlands and Italy reported no or few restrictions for
asylum seekers. However, there are some in the UK, Germany and
the Netherlands who indicated that significant restrictions are in
place (table 2).
Access to treatment for people without health
insurance and people with only state insurance
Over 75% in Italy reported no or few restrictions for those without
health insurance whereas significant or complete restrictions were
reported by the majority of respondents in Hungary (75%), Spain
(75%), the UK (56%) and the Netherlands (46%). Opinion was
divided in Germany (table 3). We included the group ‘state
insurance only’ to further explore the influence of (private) health
insurance on access to treatment and found that the vast majority of
respondents indicated that there are no restrictions (table 3). In the
UK, Germany, the Netherlands and Italy, nearly all respondents
selected no restrictions. Although 50% in Hungary indicated that
no restrictions exist for this group, one quarter selected significant
restrictions.
Access to treatment for PWID and patients who abuse
alcohol
The majority of respondents in the UK, Germany, the Netherlands
and Italy indicated no or few restrictions in antiviral treatment for
PWID infected with chronic hepatitis (table 4). In contrast, three
quarters of professionals in Hungary reported significant or
complete restrictions, with half reporting complete restrictions.
Half in Spain reported there to be significant restrictions in place,
although others indicated no or some restrictions. As with PWID,
the majority of respondents in the UK, Germany, the Netherlands
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and Italy reported no or few restrictions in treatment to be in place
for chronically infected patients who abuse alcohol. It was the
opposite in Hungary, as over 75% reported complete or significant
restrictions. Opinion was divided in Spain but suggests the existence
of restrictions in access to treatment for patients who abuse alcohol.
Discussion
Although effective treatment for chronic hepatitis B/C exists and
even cure for chronic hepatitis C, results from this study show
that access to treatment is limited for a number of vulnerable popu-
lations at risk of chronic infection in most countries we studied.
Restrictions were most often reported by experts in Hungary and
Spain, while as a group, undocumented migrants have the most
limited access to treatment. We also found discordance of opinion
about restrictions within countries, especially for groups for whom
the health care system defines access to treatment, such as undocu-
mented migrants, asylum seekers and people without health
insurance.
For screening to be considered ethical and appropriate and to
result in health gain, there should be treatment available for
diagnosed patients.24 The Wilson and Jungner criteria list availability
of effective treatment and an agreed policy on who to treat as two of
10 principles that should be met to conduct screening. Treatment
availability and eligibility are often seen from a biomedical perspec-
tive, in terms of clinical or prognostic factors only. As the six study
countries organise their health care differently, eligibility and avail-
ability can also be understood from a health system perspective. We
were interested to find out whether there are population-group
specific restrictions in place as understood by clinicians most
involved in providing it. The profile of our respondents indicates
that this aim was fulfilled; nearly all respondents are clinical special-
ists in gastroenterology, hepatology or infectious diseases and see
infected patients on a weekly basis.
As in many parts of the world, there are differences in health
system organisation between EU countries that make it an interest-
ing environment in which to conduct health systems and health
services research; in our EU-funded project, we adopted a
European perspective and sought to compare six Member States.
In Bismarckian-based welfare states, like the Netherlands and
Germany, citizens must ‘buy’ health insurance provision from
insurance companies who cannot discriminate on the basis of
individual health conditions or risk factors and contributions
depend on an individual’s financial resources.25,26 It is, therefore,
not surprising that we do observe some or significant restrictions in
access to treatment among people without health insurance here
(table 3). In Beveridge-style welfare states, like Italy, Spain and the
UK, the notion of national insurance as collective contributions
towards social and health service provision is familiar and a
national health service with associated universal free access is in
place.27 Other than a small minority who purchase private health
insurance coverage, the concept of ‘buying’ health insurance as a
means to entitlement in these universal health systems is undesirable
and alien to most. This universalism is mirrored in responses from
Italy where no or only some restrictions exist for all six patient/
population groups. It is, however, somewhat surprising that restric-
tion to treatment among those without insurance is reported in
Spain and the UK, countries with health systems where insurance
is not expected to play a role. However, both systems rely on some
form of registration to receive social support, such as a National
Insurance/NHS number in the UK or a residence permit in Spain.
Access to health care would be limited without this registration, not
because patients do not have health insurance coverage but because
those without state insurance cover are effectively considered un-
documented migrants or persons for whom health care entitlement
is uncertain.28 As a result of the financial crisis affecting Spain from
2008, various austerity and cost-containment measures were
introduced into the health and social welfare system. One change,
introduced after our survey was conducted, was the restriction of
access to health care among undocumented migrants (and others
considered to be uninsured under the universal, residence permit-
based system) to emergency and ante- and post-natal care only.29
The implication is likely to be more severe restrictions than the
already significant restrictions we observe in our results. In
Hungary, the health care system is a hybrid of a Semashko-style
Soviet system and a Bismarckian-influenced model where (social)
health insurance coverage is key to access but the legacy of out-of-
pocket payments remains.30 In fact, respondents from Hungary
reported the most restrictions among population groups, especially
among undocumented migrants, asylum seekers and people without
insurance.
Another surprising finding was the discordance about restrictions
within each country, especially for population groups for whom the
health care system or policy context defines access to treatment, such
as undocumented migrants, asylum seekers and people without
health insurance. We suggest that this lack of consensus about re-
strictions in access to treatment may either be an important explan-
ation of, or in fact caused by, the limited existence of screening
programmes that target these higher risk populations.
Undocumented migrants and asylum seekers are rarely screened
for viral hepatitis and, if found chronically infected, do not
actually reach secondary care.31 Previous studies also found lower
Table 1 Reported treatment restrictions among undocumented migrants
UK (n=9) (%) DE (n=6) (%) NL (n=22) (%) HU (n=8) (%) IT (n=9) (%) ES (n=4) (%)
No restrictions 11 17 14 0 33 25
Some restrictions 0 17 27 13 44 0
Significant restrictions 44 17 27 0 0 25
Complete restrictions 22 33 23 75 11 50
Unsure 22 17 9 13 11 0
Table 2 Reported treatment restrictions among asylum seekers?
UK (n=9) (%) DE (n=6) (%) NL (n=22) (%) HU (n=8) (%) IT (n=9) (%) ES (n=4) (%)
No restrictions 56 33 50 0 56 25
Some restrictions 0 50 23 0 22 0
Significant restriction 22 17 18 38 0 0
Complete restriction 0 0 0 25 11 50
Unsure 22 0 9 38 11 25
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preventative health care usage and poorer health outcomes from
viral hepatitis among migrant groups.32,33
This lack of consensus also suggests that specific guidance about
health care entitlement is either not available, unclear or not known
to medical professionals most involved in treating viral hepatitis. In
the absence of clear guidance about access to specific services/
provision in the health care system, professional discretion when
treating patients is likely to be applied.34 To deal with ambiguous
health care entitlement criteria, two professional coping strategies
have been suggested: ‘functional ignorance’ where the legal status of
somebody who needs health care is neither asked for nor monitored;
and ‘partial acceptance’, where, e.g. specific sub-groups of migrants
without permission to stay may have the right to certain limited
hospital and outpatient treatment in the case of sickness or
accidents, as well as to preventive care.35 The extent to which the
adoption of either strategy influences health outcomes, in terms of
screening and referral to specialist care for treatment, warrants
further investigation.
Discordance of opinion could be explained by other health system
factors. For example, within the Dutch health care system, there are
only a selected number of hospitals that are able to provide antiviral
treatment to patients without health insurance.36 The regional or-
ganisation of municipal and other public services in Germany
(La¨nder) and Spain (Comunidad Auto´noma) may also be reflected
in differing arrangements of health care including entitlement,
especially for marginalised groups like undocumented migrants. In
the case of Spain, regional authorities define the benefits package for
the local population according to local preferences and needs and
are responsible for public health service planning.37
For PWID patients and patients who abuse alcohol, restricted
treatment is less likely to be explained by the health system or
policy context and more likely due to associated clinical implica-
tions.9,10 Most professionals in most study countries, other than in
Spain and Hungary, reported no or few restrictions for PWID. Case
detection, treatment and clinical management of PWID is an
important public health issue given the high risk of HCV transmis-
sion associated with injecting drug use as well as the large
proportion of current/past injecting drug users among the burden
of chronic hepatitis C cases in the European population.4,7 However,
previous studies suggest that many PWID remain undetected and if
screened, do not reach specialist secondary care.19,32,38 Over half in
all study countries (table 4) reported the existence of some restric-
tions for patients who abuse alcohol. Alcohol use among people
infected with chronic viral hepatitis affects disease progression and
increases the risk of cirrhosis and HCC. Alcohol intake is, therefore,
undoubtedly a key treatment consideration among chronic viral
hepatitis patients and although it is not an explicit contraindication
for treatment,9 alcohol and drug use are identified as the reason for
ineligibility of treatment by 83% of treating clinicians in the UK.39
The current climate of economic austerity has led to restrictions
access to both health and social welfare provision among vulnerable
populations and to the effective new treatments that can potentially
cure chronic hepatitis C infection.40 It is, therefore, possible that
access to treatment among the populations investigated here has
become more restricted since the time of this study. The significant
health gains possible through our expanded understanding of viral
hepatitis and the scope for secondary prevention can only be realised
through expanded access to screening and antiviral treatment to
urgently find those most affected.8
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Key points
 Discordance of opinion found about access to antiviral
treatment for chronic hepatitis B/C across and within six
European countries suggests differences both in
Table 3 Reported treatment restrictions among people with no/state insurance
UK (n=9) (%) DE (n=6) (%) NL (n=22) (%) HU (n=8) (%) IT (n=9) (%) ES (n=4) (%)
No State No State No State No State No State No State
No restrictions 11 78 0 100 18 82 0 50 44 89 25 50
Some restrictions 11 0 50 0 18 9 16 25 33 11 0 50
Significant restriction 56 0 33 0 32 0 0 25 11 0 25 0
Complete restriction 0 0 0 0 14 0 75 0 11 0 50 0
Unsure 22 22 17 0 18 9 13 0 0 0 0 0
Table 4 Reported treatment restrictions among PWID and people who abuse alcohol (Alc.)
UK (n=9) (%) DE (n=6) (%) NL (n=22) (%) HU (n=8) (%) IT (n=9) (%) ES (n=4) (%)
PWID Alc. PWID Alc. PWID Alc. PWID Alc. PWID Alc. PWID Alc.
No restrictions 22 22 33 17 55 36 0 13 44 33 25 0
Some restrictions 56 56 50 67 36 59 25 13 33 44 25 50
Significant restriction 11 11 17 17 5 5 25 38 11 0 50 25
Complete restriction 0 0 0 0 5 0 50 38 11 22 0 25
Unsure 11 11 0 0 0 0 0 0 0 0 0 0
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interpretation of health care entitlement guidance and in
health systems.
 Treatment is significantly or completely restricted for un-
documented migrants in all six countries but Italy. Access
among asylum seekers differs considerably across the study
countries.
 Restriction to treatment among people without insurance
was reported in universal national health systems (Spain
and the UK).
 Most professionals in most countries, other than in Hungary
and Spain, reported no or few restrictions for people who
inject drugs.
 Without improved access to screening and treatment,
especially among marginalised and vulnerable at risk popu-
lations, the potential health gains from advances in
secondary prevention cannot be realised.
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